Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on NextCure (NXTC – Research Report), retaining the price target of $3.00.
Emily Bodnar has given her Buy rating due to a combination of factors including the promising progress of NextCure’s LNCB74 Phase 1 trial. The company has successfully moved into Cohort 3 dosing, indicating a positive safety profile with no dose-limiting toxicities observed. The rapid advancement of the trial, which began dosing in January 2025, along with the planned expansion of trial sites, is expected to enhance patient enrollment and facilitate a proof-of-concept data readout by the first half of 2026.
Furthermore, Emily sees potential in LNCB74’s efficacy, particularly in comparison to competitors in the B7-H4 ADC landscape. Despite the competitive environment, NextCure’s proprietary glucuronidase linker technology has shown superior preclinical efficacy in ovarian and breast cancer models. The recent positive data from similar ADC programs, such as AstraZeneca’s Phase 1/2a BLUESTAR trial, further supports the potential for LNCB74 to achieve favorable outcomes, reinforcing the Buy rating.
Bodnar covers the Healthcare sector, focusing on stocks such as Olema Pharmaceuticals, Femasys, and AnaptysBio. According to TipRanks, Bodnar has an average return of -9.4% and a 24.05% success rate on recommended stocks.